Anoro Ellipta

Anoro Ellipta is a combination inhaler used in the management of chronic obstructive pulmonary disease (COPD) in adults. It contains two active medicines that work together to open and relax the airways, making it easier to breathe throughout the day. Anoro Ellipta is a once-daily inhaler designed for the long-term maintenance treatment of COPD, and it is not intended for use in asthma or as a rescue inhaler during acute breathlessness.

How Anoro Ellipta Works

Anoro Ellipta combines two different classes of bronchodilator: umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta-2 adrenergic agonist (LABA). These two mechanisms complement each other by targeting different pathways in the airway smooth muscle. Umeclidinium blocks muscarinic receptors to prevent bronchoconstriction, while vilanterol activates beta-2 receptors to promote relaxation of the airway walls. Together, they provide sustained bronchodilation over a 24-hour period from a single daily dose.

Who Benefits from Anoro Ellipta

Adults with COPD who experience persistent breathlessness, exercise limitation, or frequent exacerbations despite using a single bronchodilator may benefit from Anoro Ellipta. COPD is a progressive inflammatory disease of the lungs, most commonly caused by long-term smoking, that results in airflow obstruction and breathlessness. By combining two bronchodilator classes in one device, Anoro Ellipta simplifies the treatment regimen and can offer greater symptom relief than either agent alone. Clinical trials have demonstrated that the combination improves lung function, reduces breathlessness, and decreases the frequency of COPD flare-ups.

Important Considerations

Anoro Ellipta is strictly for maintenance therapy and must not be used to relieve sudden breathlessness. Patients should always carry a short-acting reliever inhaler, such as salbutamol, for acute symptoms. Because Anoro contains a LABA component, it is not suitable for treating asthma as a standalone bronchodilator without an inhaled corticosteroid. The Ellipta device is straightforward to use and requires only one inhalation per day, which can improve adherence in patients managing complex medication routines.

How to Use Anoro Ellipta

Take Anoro Ellipta (umeclidinium + vilanterol) once daily at the same time each day. Open the cover by sliding it downward until you hear a click, this loads one dose. Breathe out fully away from the inhaler, place the mouthpiece between your lips, and inhale steadily and deeply through your mouth. Hold your breath for about 3 to 4 seconds, then breathe out slowly. Close the cover after use. No shaking is required.

Anoro should not be used more than once in 24 hours. Use it every day even when you feel well, consistent use maintains bronchodilation and reduces the risk of COPD exacerbations. It is not a rescue inhaler and will not provide rapid relief during an acute episode.

The standard adult dose of Anoro Ellipta is one inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily. The dose is fixed and should not be altered without medical advice.

No dose adjustment is required for elderly patients, as the safety and efficacy profile is consistent across age groups in clinical studies.

For patients with mild-to-moderate renal impairment, no dose adjustment is necessary. Anoro Ellipta has not been studied extensively in severe renal impairment, and caution is advised in this group.

For patients with mild-to-moderate hepatic impairment, no dose adjustment is required. Anoro Ellipta has not been studied in severe hepatic impairment; use with caution and on specialist advice only.

Anoro Ellipta is not licensed for use in children or adolescents under 18 years of age. It is not indicated for the treatment of asthma and must not be used for this purpose. If a patient with COPD is not achieving adequate symptom control on Anoro Ellipta, further assessment and potential addition of an inhaled corticosteroid or other therapy should be discussed with a respiratory specialist.

Anoro Ellipta is generally well tolerated, but like all medicines, it can cause side effects. Most side effects are related to its anticholinergic or beta-adrenergic pharmacological activity and are dose-dependent.

Common Side Effects

The following side effects occur in a notable proportion of patients and are generally mild to moderate in severity:

• Nasopharyngitis (runny or blocked nose, sore throat)
• Upper respiratory tract infection
• Urinary tract infection
• Sinusitis
• Headache
• Constipation
• Dry mouth
• Muscle spasms or cramps

Serious Side Effects

Although uncommon, the following side effects require prompt medical attention. Contact your doctor or seek emergency care if you experience any of these:

• Paradoxical bronchospasm: sudden worsening of breathing immediately after inhaling; stop use and use a short-acting reliever inhaler
• Acute narrow-angle glaucoma: eye pain, redness, blurred vision, or seeing halos around lights, particularly if the medicine enters the eyes
• Urinary retention: difficulty passing urine, especially in men with an enlarged prostate
• Serious allergic reaction (anaphylaxis): swelling of the face, lips, tongue or throat, difficulty breathing, or widespread rash
• Cardiac arrhythmias: palpitations, irregular or fast heartbeat

Inform your doctor of any unusual symptoms, particularly any changes in heart rhythm or eye-related symptoms.

Cardiovascular and Respiratory Warnings

Anoro Ellipta contains vilanterol, a LABA, which may cause cardiovascular effects including increased heart rate, palpitations, and, rarely, arrhythmias. It should be used with particular caution in patients with pre-existing cardiovascular disease, including ischaemic heart disease, hypertension, or cardiac arrhythmias. Anoro Ellipta must not be used as a rescue bronchodilator; patients should always have access to a fast-acting inhaler such as salbutamol. If breathing worsens suddenly after use, this may indicate paradoxical bronchospasm and Anoro should be discontinued immediately.

Anticholinergic Precautions and Drug Interactions

Umeclidinium has anticholinergic properties that can cause urinary retention, particularly in men with benign prostatic hyperplasia, and may worsen narrow-angle glaucoma. Care must be taken to avoid the medicine entering the eyes. Anoro Ellipta should not be used with other long-acting muscarinic antagonists or long-acting beta-2 agonists concurrently, as this would duplicate the pharmacological effect without additional benefit and increase side effect risk. Use alongside other anticholinergic medicines can amplify anticholinergic adverse effects.

Anoro Ellipta has not been studied in pregnancy, and its safety during breastfeeding has not been established. It should only be used in pregnancy or lactation if the potential benefit clearly outweighs any theoretical risk. Patients are generally not expected to experience impaired driving ability with Anoro Ellipta at recommended doses. Alcohol has no known interaction with this inhaler.

Anoro Ellipta is contraindicated in the following situations:

• Hypersensitivity to umeclidinium, vilanterol, or any excipient in the formulation (including lactose, which contains milk protein)
• Use in patients with severe milk protein allergy
• Use as a treatment for acute episodes of bronchospasm or as a rescue inhaler
• Use in asthma without concomitant inhaled corticosteroid therapy
• Patients under 18 years of age (no safety data available)
• Concomitant use with other LAMA/LABA-containing products
• Caution (not absolute contraindication) in severe renal or severe hepatic impairment
• Caution in patients with narrow-angle glaucoma (risk of acute angle closure)
• Caution in patients with urinary retention or symptomatic benign prostatic hyperplasia